[go: up one dir, main page]

PE20080689A1 - KINASE INHIBITORS AMINE DERIVATIVES - Google Patents

KINASE INHIBITORS AMINE DERIVATIVES

Info

Publication number
PE20080689A1
PE20080689A1 PE2007000962A PE2007000962A PE20080689A1 PE 20080689 A1 PE20080689 A1 PE 20080689A1 PE 2007000962 A PE2007000962 A PE 2007000962A PE 2007000962 A PE2007000962 A PE 2007000962A PE 20080689 A1 PE20080689 A1 PE 20080689A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
amine
pyrrolo
pyrrolidin
Prior art date
Application number
PE2007000962A
Other languages
Spanish (es)
Inventor
Matthew Stephen Corbett
Goss Stryker Kauffman
Kevin Daniel Freeman-Cook
Blaise Scott Lippa
Michael Joseph Luzzio
Joel Morris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20080689A1 publication Critical patent/PE20080689A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDA A UN DERIVADO DE AMINA DE FORMULA (I), DONDE A ES UN BICICLO FUSIONADO; u ES UN ENTERO DE 0 A 3; V ES N O CR7; W Y X SON N O CR8; Y ES CH, N O NH; Z ES CH O N; D Y E SON C O N; L ES -(CR3R4)m- O C(O); m ES UN ENTERO DE 1 A 6; R1 Y R2 SON H, ALQUILO C1-C6, CICLOALQUILO C3-C10, CICLOALQUENILO C5-C10, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C6, CF3; R5 ES OR13, NR14R15, NR11C(O)R10, ENTRE OTROS; R6 ES ALQUILO C1-C6 O CICLOALQUILO C3-C10; R7 ES HALOGENO, OH, CF3, ENTRE OTROS; R8 ES H, HALO, CN, OH O ALQUILO C1-C6; R10 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R11 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R13 ES ALQUILO C1-C6, CICLOALQUILO C3-C10, CICLOALQUENILO C5-C10, ENTRE OTROS; R14 ES H, CF3, ALQUILO C1-C6, ENTRE OTROS; R15 ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (3S)-3-{[(4-CLOROFENIL9AMINO]METIL}-1-(5-METIL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)PIRROLIDIN-3-AMINA, 3-({[2-FLUORO-3-(TRIFLUOROMETIL)FENIL]AMINO}METIL)-1-(5-METIL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)PIRROLIDIN-3-AMINA, (3S)-1-(5-METIL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-3-{[3-(TRIFLUOROMETIL)FENIL]AMINO}METIL)PIRROLIDIN-3-AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA AKT Y/O P70S6K1 Y SON UTILES EN EL TRATAMIENTO DE CELULAS CANCEROSASREFERRED TO AN AMINE DERIVATIVE OF FORMULA (I), WHERE A IS A FUSED BIKE; u IS AN INTEGER FROM 0 TO 3; V IS NO CR7; W AND X ARE NO CR8; Y IS CH, N O NH; Z IS CH O N; D AND E ARE C O N; L ES - (CR3R4) m- O C (O); m IS AN INTEGER FROM 1 TO 6; R1 AND R2 ARE H, C1-C6 ALKYL, C3-C10 CYCLOALKYL, C5-C10 CYCLOALKENYL, AMONG OTHERS; R3 AND R4 ARE H, C1-C6 ALKYL, CF3; R5 IS OR13, NR14R15, NR11C (O) R10, AMONG OTHERS; R6 IS C1-C6 ALKYL OR C3-C10 CYCLOALKYL; R7 IS HALOGEN, OH, CF3, AMONG OTHERS; R8 IS H, HALO, CN, OH OR C1-C6 ALKYL; R10 IS H, C1-C6 ALKYL, C2-C6 ALKYL, AMONG OTHERS; R11 IS H, C1-C6 ALKYL, C2-C6 ALKYL, AMONG OTHERS; R13 IS C1-C6 ALKYL, C3-C10 CYCLOALKYL, C5-C10 CYCLOALKENYL, AMONG OTHERS; R14 IS H, CF3, C1-C6 ALKYL, AMONG OTHERS; R15 IS C1-C6 ALKYL, C2-C6 ALKYL, C2-C6 ALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (3S) -3 - {[(4-CHLOROPHENYL9AMINE] METHYL} -1- (5-METHYL-7H-PYRROLO [2,3-d] PYRIMIDIN-4-IL) PYRROLIDIN-3-AMINE, 3 - ({[2-FLUORO-3- (TRIFLUOROMETIL) PHENYL] AMINO} METHYL) -1- (5-METHYL-7H-PYRROLO [2,3-d] PYRIMIDIN-4-IL) PYRROLIDIN-3-AMINE, ( 3S) -1- (5-METHYL-7H-PYRROLO [2,3-d] PYRIMIDIN-4-IL) -3 - {[3- (TRIFLUOROMETHYL) PHENYL] AMINO} METHYL) PYRROLIDIN-3-AMINE, AMONG OTHERS . IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF KINASE AKT AND / OR P70S6K1 AND ARE USEFUL IN THE TREATMENT OF CANCER CELLS

PE2007000962A 2006-07-26 2007-07-25 KINASE INHIBITORS AMINE DERIVATIVES PE20080689A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82044106P 2006-07-26 2006-07-26

Publications (1)

Publication Number Publication Date
PE20080689A1 true PE20080689A1 (en) 2008-06-14

Family

ID=38963178

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000962A PE20080689A1 (en) 2006-07-26 2007-07-25 KINASE INHIBITORS AMINE DERIVATIVES

Country Status (7)

Country Link
AR (1) AR062050A1 (en)
CL (1) CL2007002188A1 (en)
GT (1) GT200700062A (en)
PE (1) PE20080689A1 (en)
TW (1) TW200817408A (en)
UY (1) UY30499A1 (en)
WO (1) WO2008012635A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011628D1 (en) 2006-07-06 2011-02-10 Array Biopharma Inc DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
CN101631778B (en) 2006-07-06 2013-05-08 阵列生物制药公司 Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
UA99284C2 (en) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані P70 s6 kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
KR101650956B1 (en) 2007-07-05 2016-08-24 어레이 바이오파마 인크. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
KR101624361B1 (en) 2007-07-05 2016-05-25 어레이 바이오파마 인크. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
CN101965347B (en) 2008-01-09 2013-01-02 阵列生物制药公司 Pyrazolopyridines as kinase inhibitors
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
ES2422733T3 (en) 2008-01-09 2013-09-13 Array Biopharma Inc Hydroxylated pyrimidylcyclopentanes as AKT protein kinase inhibitors
AR071717A1 (en) 2008-05-13 2010-07-07 Array Biopharma Inc PIRROLO [2,3-B] CHK1 AND CHK2 QUINASE INHIBITING PIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME IN THE TREATMENT AND PREVENTION OF CANCER.
AU2013218743B2 (en) * 2008-05-13 2016-04-28 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
AR074072A1 (en) 2008-11-11 2010-12-22 Lilly Co Eli COMPOSITE OF IMIDAZOL -PIPERIDIN -PIRROL-PIRIMIDIN-6-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT MULTIFORM GLIOBLASTOMA
AR074830A1 (en) 2008-12-19 2011-02-16 Cephalon Inc PIRROLOTRIAZINAS AS ALK AND JAK2 INHIBITORS
DE102009005193A1 (en) * 2009-01-20 2010-07-22 Merck Patent Gmbh Novel heterocyclic compounds as MetAP-2 inhibitors
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
CN102711473B (en) 2009-09-04 2016-11-09 比奥根Ma公司 Bruton's tyrosine kinase inhibitors
US8343977B2 (en) 2009-12-30 2013-01-01 Arqule, Inc. Substituted triazolo-pyrimidine compounds
US9370567B2 (en) 2010-11-16 2016-06-21 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and WEE 1 kinase inhibitors
ES2617339T3 (en) 2010-12-16 2017-06-16 Calchan Limited ASK1 inhibitor pyrrolopyrimidine derivatives
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CA2844699C (en) 2011-04-01 2019-05-07 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
CN103841976A (en) 2011-04-01 2014-06-04 基因泰克公司 Combinations of AKT AND MEK inhibitor compounds, and methods of use
PT2755958T (en) * 2011-09-12 2017-11-14 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
AR091273A1 (en) 2012-06-08 2015-01-21 Biogen Idec Inc PYRIMIDINYL TIROSINE KINASE INHIBITORS
DK3176170T3 (en) 2012-06-13 2019-01-28 Incyte Holdings Corp SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA3130452C (en) 2013-04-19 2023-10-31 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX373169B (en) 2015-02-20 2020-04-24 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
PE20190175A1 (en) 2016-03-28 2019-02-01 Incyte Corp PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
BR112019001158A2 (en) 2016-07-21 2019-04-30 Biogen Ma, Inc. succinate forms and bruton tyrosine kinase inhibitor compositions
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
CN112867716B (en) 2018-05-04 2024-09-13 因赛特公司 Solid forms of FGFR inhibitors and methods of making the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2024513575A (en) 2021-04-12 2024-03-26 インサイト・コーポレイション Combination therapy including FGFR inhibitor and Nectin-4 targeting agent
AR126102A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors

Also Published As

Publication number Publication date
CL2007002188A1 (en) 2008-02-01
AR062050A1 (en) 2008-08-10
TW200817408A (en) 2008-04-16
UY30499A1 (en) 2008-02-29
WO2008012635A3 (en) 2008-05-08
GT200700062A (en) 2008-08-08
WO2008012635A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
PE20080689A1 (en) KINASE INHIBITORS AMINE DERIVATIVES
IL177962A0 (en) Compounds and methods for treating dyslipidemia
PH12012501386A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
PE20081393A1 (en) QUINOLINE DERIVATIVES AS INHIBITORS OF CSF-1R
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
EA200970585A1 (en) BENZAMIDE DERIVATIVES AS AGONISTS OF EP RECEPTORS
GB0413087D0 (en) Therapeutic compounds
CL2009001152A1 (en) Compounds derived from n- (4- (nitrogen cycloalkyl-1-yl) -1h-pyrrolo [2,3-b] pyridin-3-yl) amide, kinase inhibitors; Preparation process; pharmaceutical composition; and its use for the treatment of a proliferative disease.
TW200726739A (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
ATE433981T1 (en) HETEROCYCLIC COMPOUNDS
CO5550421A2 (en) INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASE
TW200612936A (en) Indole derivatives
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
TW200640879A (en) Amide derivatives
PE20081368A1 (en) DERIVATIVES OF AZABICYCLE [4.1.0] HEPTANE AS INHIBITORS OF THE RECAPTATION OF SEROTONIN, DOPAMINE AND NOREPINEPHRINE
PE20091436A1 (en) SULFONAMID DERIVATIVES SUBSTITUTED AS B1R MODULATORS
SG162803A1 (en) Imidazole based lxr modulators
MX2009009466A (en) Tricyclic compounds useful in treating iron disorders.
UY29312A1 (en) PIPERAZIN-1-CARBOXAMIDAS N, 4, SUBSTITUTES AND THEIR DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
ATE409179T1 (en) TETRALIN AND INDANDE DERIVATIVES AND THEIR APPLICATIONS AS 5-HT ANTAGONISTS

Legal Events

Date Code Title Description
FD Application declared void or lapsed